Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer

Ken, Ito; Satoshi, Yuki; Hiroshi, Nakatsumi et al.

Supportive Care in Cancer, 2022, 30(6), 5351-5359

Permalink : https://hdl.handle.net/2115/85674

このアイテムのアクセス数:561件（2026-02-08 17:27 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
https://doi.org/10.1007/s00520-022-06936-4     1

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
metadata only access
URI
https://hdl.handle.net/2115/85674
タイトル
Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer
著者
Ken, Ito ; Satoshi, Yuki ; Hiroshi, Nakatsumi ; Kawamoto, Yasuyuki ; Harada, Kazuaki ; Nakano, Shintaro ; Saito, Rika ; Ando, Takayuki ; Sawada, Kentaro ; Yagisawa, Masataka ; Ishiguro, Atsushi ; Dazai, Masayoshi ; Iwanaga, Ichiro ; Hatanaka, Kazuteru ; Sato, Atsushi ; Matsumoto, Ryusuke ; Shindo, Yoshiaki ; Tateyama, Miki ; Muranaka, Tetsuhito ; Katagiri, Masaki ; Yokota, Isao ; Sakata, Yuh ; Sakamoto, Naoya ; Komatsu, Yoshito
著者名
Ken, Ito
著者名
Satoshi, Yuki
著者名
Hiroshi, Nakatsumi
e-Rad_Researcher
60755601
著者名
Kawamoto, Yasuyuki
著者名
Harada, Kazuaki
著者名
Nakano, Shintaro
著者名
Saito, Rika
著者名
Ando, Takayuki
著者名
Sawada, Kentaro
著者名
Yagisawa, Masataka
著者名
Ishiguro, Atsushi
著者名
Dazai, Masayoshi
著者名
Iwanaga, Ichiro
著者名
Hatanaka, Kazuteru
著者名
Sato, Atsushi
著者名
Matsumoto, Ryusuke
著者名
Shindo, Yoshiaki
著者名
Tateyama, Miki
著者名
Muranaka, Tetsuhito
著者名
Katagiri, Masaki
e-Rad_Researcher
20761414
著者名
Yokota, Isao
著者名
Sakata, Yuh
e-Rad_Researcher
10334418
著者名
Sakamoto, Naoya
e-Rad_Researcher
60333598
著者名
Komatsu, Yoshito
言語
英語
キーワード
Dysgeusia
Taste disorder
Chemotherapy
Gastrointestinal cancer
Polaprezinc
Zinc acetate hydrate
発行日
2022-06-01
出版者
Springer
収録物名
Supportive Care in Cancer
巻(号)
30(6)
ページ
5351-5359
抄録
Purpose Dysgeusia is an adverse event caused by chemotherapy. Although retrospective studies have shown zinc administration improves dysgeusia, there have been no prospective studies. The present study examined effects of zinc therapy on dysgeusia in patients with gastrointestinal cancer. Methods This multicenter, prospective, observational study enrolled patients with dysgeusia during chemotherapy treatment. Patients received no intervention (control), polaprezinc p.o., or zinc acetate hydrate p.o., and serum zinc levels were measured at 0 (baseline), 6, and 12 weeks. Dysgeusia was assessed using CTCAE v5.0 and subjective total taste acuity (STTA) criteria using questionnaires at baseline and 12 weeks. Results From February 2020 to June 2021, 180 patients were enrolled from 17 institutes. There were no differences in mean baseline serum zinc levels among the groups (67.3, 66.6, and 67.5 mu g/dL in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. P = 0.846). The changes in mean serum zinc levels after 12 weeks were - 3.8, + 14.3, and + 46.6 mu g/dL, and the efficacy rates of dysgeusia were 33.3%, 36.8%, and 34.6% using CTCAE and 33.3%, 52.6%, 32.7% using STTA in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. The STTA scores improved in all groups, with significant improvement observed in the polaprezinc group compared with the no intervention group (P = 0.045). Conclusion There was no significant correlation between the degree of serum zinc elevation and improvement in dysgeusia, suggesting that polaprezinc, but not zinc acetate hydrate, was effective in improving chemotherapy-induced dysgeusia.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
PISSN
0941-4355
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.1007/s00520-022-06936-4